Xinlitai announced that recently, the company received the “Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of the innovative small molecule drug SAL0140 tablets independently developed by the company to treat chronic kidney disease.

Xinlitai announced that recently, the company received the “Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of the innovative small molecule drug SAL0140 tablets independently developed by the company to treat chronic kidney disease.